- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05369884
Efficacy and Safety of WPQW Granule for Overlap of NERD and IBS-D
10 de maio de 2022 atualizado por: Xiyuan Hospital of China Academy of Chinese Medical Sciences
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of WPQW Granule for Overlap of Non-Erosive Reflux Disease(NERD) and Diarrhea Predominant Diarrhea Irritable Bowel Syndrome(IBS-D)
Non-erosive reflux disease(NERD)and Diarrhea-Predominant Irritable Bowel Syndrome(IBS-D)are both the common refractory gastrointestinal diseases.
Patients, who suffered from overlapping symptoms of NERD and IBS-D, present more serious symptom manifestation, anxiety, and worse life quality than those with solely disease.
There is lack of effective treatment for overlapping gastrointestinal symptoms.
Traditional Chinese Medicine (TCM) syndrome differentiation and treatment has the advantages of overall regulation and individualized treatment, but lack of high-level evidence.
The purpose of this study is to evaluate the efficacy and safety of WPQW granule for the treatment of NERD overlapping IBS-D.
Visão geral do estudo
Status
Recrutamento
Intervenção / Tratamento
Descrição detalhada
Gastroesophageal reflux disease (GERD) is a chronic relapsing acid-peptic disorder that is caused by the reflux of gastric or duodenum content.
Non-erosive reflux disease(NERD), which account for 70%, is the most common type of GERD in the Asian population.
Diarrhea-Predominant Irritable Bowel Syndrome(IBS-D)is the mainly subtype of IBS, and the prevalence was found to be 46% in IBS.
Both diseases aforementioned are common and frequent chronic diseases in the world, and the pathogenesis of which has not been fully defined.
Current studies have shown that GERD can present in patients with IBS, vice versa.
Up to 79% of patients with IBS co-exist with GERD-like symptoms, and 71% of patients with GERD co-exist with IBS-like symptoms.
For those patients, they suffer from more serious symptom manifestation, anxiety, and worse life quality those with solely disease.
The diagnosis and treatment of Functional gastrointestinal disorders (FGIDs) mostly based on the idea of segmental diagnosis and single-target therapy in modern medicine, and there is lack of effective treatment for overlapping gastrointestinal symptoms.
The advantages of holistic diagnosis therapy and individualized treatment in Traditional Chinese Medicine(TCM)have attracted international attention, but there is still lack of high-level evidence-based medical evidence for the treatment of symptom overlap in FGIDs in TCM.
In this study, we propose to conduct a multicenter, randomized, double-blind, placebo-controlled clinical study of WPQW granule for the treatment of NERD overlapping IBS-D to evaluate the efficacy and safety of WPQW granule with the aim of obtaining high-level evidence-based medical evidence.
Tipo de estudo
Intervencional
Inscrição (Antecipado)
216
Estágio
- Fase inicial 1
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Contato de estudo
- Nome: Fengyun Wang, M.D
- Número de telefone: +86(010)62835248
- E-mail: wfy811@163.com
Locais de estudo
-
-
Beijing
-
Beijing, Beijing, China, 100091
- Recrutamento
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
-
Contato:
- Fengyun Wang, M.D
- Número de telefone: +86(010)62835248
- E-mail: wfy811@163.com
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos a 70 anos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Patients diagnosed with NERD and IBS-D simultaneously
- Patients who present cardinal symptoms like reflux, heartburn, abdominal pain/bloating, diarrhea, etc
- Patients diagnosed with syndrome of intermingled cold and heat of traditional Chinese medicine
- Patients have informed consent and are willing to receive corresponding treatment
Exclusion Criteria:
- Patients with hiatal hernia
- Patients with upper gastrointestinal bleeding, peptic ulcer, gastrointestinal tumor, chronic atrophic gastritis with dysplasia
- Patients with other serious organic diseases, such as acute cardiovascular disease, acute and chronic pancreatitis, cirrhosis, abnormal liver function (transaminases more than 1.5 times of normal value), abnormal thyroid function, diabetes mellitus with a history of more than 10 years, chronic renal insufficiency, hematologic disorders, and hematologic disorders, etc
- Patients with neurological disease or psychiatric impairment like severe anxiety, depression requiring long-term drug treatment
- Patients who cannot stop taking acid suppressants for a long time
- Alcohol or drug dependency or abuse
- Pregnant or lactating women
- Patients who have a history of allergies to all the test drugs
- Patients who are participating in other clinical trials or have participated in other clinical trials within 3 months
- Patients who, in the opinion of the investigator, are not suitable to participate in clinical trial
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Triplo
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental group
Oral administration of WPQW granule with warm water,2 sachets each time, 3 times a day, 1.5-2 hours after a meal.
The medication period was 4 weeks.
|
WPQW granule, 2 sachets / time, 3 times / day.
|
|
Comparador de Placebo: Control group
Oral administration of WPQW granule simulant,which containing 5% WPQW granule,with warm water,2 sachets each time, 3 times a day, 1.5-2 hours after a meal.
The medication period was 4 weeks.
|
WPQW granule simulant, 2 sachets / time, 3 times / day.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change of visual analogue scale (VAS) score of symptoms of reflux and heartburn
Prazo: baseline, 4 weeks during treatment period, 4 weeks during follow-up period
|
During the medication period, the patients recorded the reflux and heartburn episodes (frequency and duration) within 24 hours per day on the symptom diary card, and VAS scores for reflux and heartburn symptoms was calculated as the mean score of each symptom in the past week.
The episodes in the week before medication were used as the baseline, the mean score of any symptom decreased ≥50% from the baseline was recorded as response after weekly treatment, and the number of response weeks was considered effective if it was greater than 50% of the weeks of the whole treatment period.
|
baseline, 4 weeks during treatment period, 4 weeks during follow-up period
|
|
Change of visual analogue scale (VAS) score of symptoms of abdominal pain and diarrhea
Prazo: baseline, 4 weeks during treatment period, 4 weeks during follow-up period
|
During the medication period, the patients recorded the of abdominal pain (pain severity and frequency) and diarrhea (stool consistency and frequency based on Bristol stool form scale) within 24 hours per day on the symptom diary card.
VAS score was conducted for the most severe abdominal pain, and the mean score was calculated for each week, with the week of episodes prior to medication administration as the baseline.
It was considered effective when the weekly mean score decrease of at least 30% from baseline and the days of at least once type 6 or type 7 stool Bristol stool form every week decrease of at least 30% from baseline, referring to the efficacy evaluation of the technical guidelines for clinical studies of Chinese medicine for IBS published in 2017.
|
baseline, 4 weeks during treatment period, 4 weeks during follow-up period
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change of traditional Chinese Medicine syndrome score
Prazo: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
The symptoms related to syndrome of intermingled cold and heat were scored.
The cardinal symptom was scored 0, 2, 4, 6 and the secondary symptom scored 0, 1, 2, 3 respectively according to severity of each symptom.
Total symptom score represented the syndrome score.
Reduction in syndrome score represented Improvement.
|
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
|
Change of 36-item short-form (SF-36) score
Prazo: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
Health status was evaluated by a 36-item short-form (SF-36) containing eight health concepts.
If the score descends, it indicates that the patient's condition has improved.
|
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
|
Change of FGI-checklist score
Prazo: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
A 20-item FGI-checklist was used to evaluate comprehensive symptom severity of Functional Gastrointestinal Disorder (FGID), which covering esophageal, dyspeptic and bowel symptoms.
If the score descends, it indicates that the patient's condition has improved.
|
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
|
Change of Hospital Anxiety and Depression Scale (HAD) score
Prazo: baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
Hospital Anxiety and Depression Scale (HAD) score was used to evaluate the efficacy of experimental drug.
Reduction in total score represented Improvement
|
baseline, week 2, week 4 during treatment period, week 6 and week 8 during follow-up period
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Colaboradores
Investigadores
- Investigador principal: Xudong Tang, M.D, China Academy of Chinese Medical Sciences
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de dezembro de 2021
Conclusão Primária (Antecipado)
1 de maio de 2023
Conclusão do estudo (Antecipado)
1 de maio de 2023
Datas de inscrição no estudo
Enviado pela primeira vez
8 de maio de 2022
Enviado pela primeira vez que atendeu aos critérios de CQ
10 de maio de 2022
Primeira postagem (Real)
11 de maio de 2022
Atualizações de registro de estudo
Última Atualização Postada (Real)
11 de maio de 2022
Última atualização enviada que atendeu aos critérios de controle de qualidade
10 de maio de 2022
Última verificação
1 de dezembro de 2021
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Processos Patológicos
- Doença
- Sinais e Sintomas Digestivos
- Doenças Gastrointestinais
- Doenças Colônicas Funcionais
- Doenças do cólon
- Doenças Intestinais
- Distúrbios da Motilidade Esofágica
- Distúrbios da Deglutição
- Doenças Esofágicas
- Síndrome
- Síndrome do intestino irritável
- Diarréia
- Refluxo gastroesofágico
Outros números de identificação do estudo
- ZYYCXTD-C-202010
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
NÃO
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .